Imbruvica
| Imbruvica (ibrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor approved to treat Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease and currently being evaluated in multiple types of cancer and for other serious diseases. |
Type of Molecule
Small MoleculeTarget
BTKProduct Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted, Approved) |
|---|---|---|
| Chronic Graft versus Host Disease (cGVHD) | US, EU |
Approved
|
| Diffuse Large B-cell Lymphoma (DLBCL) | US, EU |
Phase 3
|
| Follicular Lymphoma (FL) | US, EU |
Phase 3
|
| Relapsed/Refractory Marginal Zone Lymphoma (MZL) | US, EU |
Approved
|
| Pancreatic Cancer | US, EU |
Phase 3
|
| Solid Tumors | US, EU |
Phase 2
|